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A practical approach for reliable detection of AmpC
Beta-Lactamase producing Enterobacteriaceae
Abstract
In this prospective study all Enterobacteriaceae isolates (n=2129) recovered in the clinical microbiology
laboratory during October 2009 to April 2010 were analyzed for AmpC production. CLSI cefoxitin and
cefotetan susceptibility breakpoints and CLSI critical ESBL diameters were used to screen for potential
AmpC producers. In total, 305 isolates (211 potential AmpC producers, 94 AmpC screen negative
isolates as control group) were further analyzed by multiplex PCR for the detection of plasmid-encoded
ampC beta-lactamase genes and by ampC promoter sequence analysis (considered as gold standard).
Cefoxitin and cefotetan were assessed as primary screening markers. Sensitivities of cefoxitin and
cefotetan for detection of AmpC production were 97.4% and 52.6%, specificities were 78.7% and
99.3%, respectively. As a phenotypic confirmation test, the Etest AmpC and the cefoxitin/cloxacillin
double disk synergy method (CC-DDS) were compared. Sensitivities for the Etest AmpC and the
CC-DDS method were 77.4% and 97.2, respectively; specificity was 100% for both methods. The
results of the Etest AmpC were inconclusive for 10 isolates. With the CC-DDS method 2 inconclusive
results were observed. Based on this study we propose a comprehensive diagnostic flow-chart for
detection of AmpC production consisting of a simple phenotypic screening and a single phenotypic
confirmation test with inconclusive results being resolved by molecular analysis. For the proposed
flow-chart using i) cefoxitin as screening marker for AmpC production ii) the CC-DDS method as
phenotypic confirmation and iii) molecular methods in case of inconclusive results, the sensitivity and
specificity for AmpC detection would have been 97.4 and 100%, respectively, with respect to the
studied isolates. The phenotypic methods used in the AmpC algorithm are simple to perform, and easy
to implement in the diagnostic laboratory.
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 2 
Abstract 28 
In this prospective study all Enterobacteriaceae isolates (n=2129) recovered in the 29 
clinical microbiology laboratory during October 2009 to April 2010 were analyzed for 30 
AmpC production. CLSI cefoxitin and cefotetan susceptibility breakpoints and CLSI 31 
critical ESBL diameters were used to screen for potential AmpC producers. In total, 305 32 
isolates (211 potential AmpC producers, 94 AmpC screen negative isolates as control 33 
group) were further analyzed by multiplex PCR for the detection of plasmid-encoded 34 
ampC beta-lactamase genes and by ampC promoter sequence analysis (considered as gold 35 
standard). Cefoxitin and cefotetan were assessed as primary screening markers. 36 
Sensitivities of cefoxitin and cefotetan for detection of AmpC production were 97.4% and 37 
52.6%, specificities were 78.7% and 99.3%, respectively. As a phenotypic confirmation 38 
test, the Etest AmpC and the cefoxitin/cloxacillin double disk synergy method (CC-DDS) 39 
were compared. Sensitivities for the Etest AmpC and the CC-DDS method were 77.4% 40 
and 97.2, respectively; specificity was 100% for both methods. The results of the Etest 41 
AmpC were inconclusive for 10 isolates. With the CC-DDS method 2 inconclusive results 42 
were observed. Based on this study we propose a comprehensive diagnostic flow-chart for 43 
detection of AmpC production consisting of a simple phenotypic screening and a single 44 
phenotypic confirmation test with inconclusive results being resolved by molecular 45 
analysis. For the proposed flow-chart using i) cefoxitin as screening marker for AmpC 46 
production ii) the CC-DDS method as phenotypic confirmation and iii) molecular methods 47 
in case of inconclusive results, the sensitivity and specificity for AmpC detection would 48 
have been 97.4 and 100%, respectively, with respect to the studied isolates. The 49 
phenotypic methods used in the AmpC algorithm are simple to perform, and easy to 50 
implement in the diagnostic laboratory. 51 
 52 
 53 
 54 
 3 
Introduction 55 
In recent years, the prevalence of infections with multidrug-resistant 56 
Enterobacteriaceae has steadily increased (18). Enterobacteriaceae producing AmpC 57 
beta-lactamases (AmpCs) have become a major therapeutic challenge. The detection of 58 
AmpC producing Klebsiella spp., Escherichia coli, P. mirabilis and Salmonella spp. is of 59 
significant clinical relevance since AmpC producers may appear susceptible to third 60 
generation cephalosporins when initially tested (13, 27, 28)..This may lead to inappropriate 61 
antimicrobial regimens and therapeutic failure (24). Thus, a simple and reliable detection 62 
procedure for AmpC producers is needed. 63 
Many Gram-negative bacteria harbour chromosomal ampC beta-lactamase genes, which 64 
are constitutively expressed at low level. In general, expression of chromosomally located 65 
ampC genes is inducible by beta-lactam antibiotics, such as cefoxitin, cefotetan and 66 
imipenem, and mediated by the regulator AmpR. Mutations in the repressor gene ampD 67 
are the most common cause of constitutive (hyper-) production of AmpC beta-lactamases 68 
(23). AmpC beta-lactamases degrade penicillins, expanded-spectrum cephalosporins with 69 
the exception of cefepime and cefpirome, cephamycins, monobactams and beta-lactam 70 
inhibitors. In contrast to ESBLs, AmpC beta lactamases are inhibited by boronic acid and 71 
cloxacillin (2, 9, 25), In E. coli, regulation of chromosomal ampC expression differs 72 
significantly from that of other Enterobacteriaceae. In E. coli ampC is regulated by a weak 73 
promoter and a strong attenuator resulting in a constitutive low level ampC expression 74 
(11). Diverse mutations in the ampC promoter region leading to overexpression have been 75 
described (3, 4, 7, 11, 12, 24, 29). In addition to chromosomal ampC, Enterobacteriaceae 76 
can acquire plasmid encoded ampC genes (9). In general, plasmid-encoded AmpC beta-77 
lactamases are expressed constitutively and are readily detected by a multiplex PCR (17).  78 
Different phenotypic AmpC detection tests have been described in the literature (9). A 79 
standardized diagnostic approach integrating screening and confirmation tests for detection 80 
of AmpC beta-lactamase producing Enterobacteriaceae has not been established to date. 81 
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This study aimed at developing a comprehensive diagnostic flow-chart integrating a simple 82 
phenotypic screening and confirmation for implementation in the routine diagnostic 83 
laboratory. 84 
 85 
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Methods 109 
 110 
Clinical isolates.  111 
In this prospective study all non-duplicate clinical Enterobacteriaceae isolates (n=2129) 112 
from the diagnostic laboratory isolated over a period of 7 month from October 2009 until 113 
April 2010 were screened for AmpC production (Figure 2). Only isolates that were 114 
considered clinically relevant were included, i.e. isolates that were considered as normal 115 
flora or commensals were disregarded. The isolates included in this study consist of 116 
Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabillis, Proteus 117 
vulgaris, Citrobacter koseri, Salmonella enterica. and Citrobacter koseri. With the 118 
exception of E. coli, we excluded species with known chromosomal AmpC production, 119 
e.g. Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, Serratia 120 
marcescens, Hafnia alvei, and Morganella morganii (9). 121 
 122 
Susceptibility testing. 123 
For susceptibility testing the disk diffusion method according to Kirby-Bauer was used. 124 
Antibiotic disks were purchased from Becton Dickinson (Franklin Lakes, NJ, USA) and 125 
results were interpreted according to the CLSI 2009 guidelines (5). For cefoxitin (30 126 
µg/disk) and cefotetan (30 µg/disk) screening cut offs of ≤ 18 mm and ≤ 16 mm were used, 127 
respectively (CLSI susceptible breakpoints). In addition, the following ESBL CLSI 128 
screening cut off values for third generation cephalosporins were used to select for 129 
potential AmpC producing isolates: cefpodoxime (10 µg/disk)  ≤ 17 mm, ceftazidime (30 130 
µg/disk) ≤ 22 mm, cefotaxime (30 µg/disk) ≤ 27 mm, and ceftriaxone (30 µg/disk) ≤ 25 131 
mm. Susceptibility testing was performed on Mueller-Hinton agar (bioMérieux, Marcy 132 
L’Etoile, France) using McFarland 0.5 from overnight cultures followed by incubation at 133 
35° C for 16-18 h.  134 
 135 
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Phenotypic AmpC confirmation testing. 136 
The Etest AmpC (AB bioMérieux, Solna, Sweden) was performed according to the 137 
manufacturer’s instructions. The test principle comprises a strip impregnated with a 138 
concentration gradient of cefotetan on one half and cefotetan with cloxacillin on the other 139 
half of the strip. MICs of cefotetan alone and cefotetan with cloxacillin were determined as 140 
recommended by the manufacturer. Ratios of cefotetan versus cefotetan/cloxacillin ≥ 8 141 
were considered positive for AmpC beta-lactamase production.  142 
The cefoxitin/cloxacillin double disc synergy test (CC-DDS) was performed as described 143 
(25). This test is based on the inhibitory effect of cloxacillin on AmpC. Disks containing 144 
30 µg cefoxitin and 30 µg cefoxitin / 200 µg cloxacillin were manufactured for this study 145 
(Liofilchem, Roseto degli Abruzzi, Italy). The strains were inoculated on Mueller-Hinton 146 
agar using McFarland 0.5 followed and incubated at 35° C for 16-18 h. A difference of the 147 
inhibition zones of cefoxitin/cloxacillin minus cefoxitin alone of ≥ 4 mm was considered 148 
indicative for AmpC production. 149 
 150 
ampC promoter sequencing (E. coli only). 151 
DNA was extracted from colonies grown on sheep blood agar medium using the InstaGene 152 
Matrix (Bio-Rad, Switzerland) following the manufacturer’s instruction. For the ampC 153 
promoter mutation analysis a 271-bp fragment was amplified using primers AB1(5’-154 
GATCGTTCTGCCGCTGTG-3`) and ampC2 (5’-GGGCAGCAAATGTGGAGCAA-3`) 155 
(4). PCR amplicons were purified with the QIAquick PCR purification kit (Qiagen, 156 
Hombrechtikon, Switzerland) followed by cycle sequencing using the BigDye reagent kit 157 
(Applied Biosystems, Switzerland).  Sequence analysis was performed on an ABI Prisma 158 
3100 DNA sequencer (Applied Biosystems, Switzerland) following standard protocols. 159 
Sequences were analyzed and edited using Lasergene 7 MegAlign software (DNASTAR 160 
Inc., USA). The ampC promoter sequences were compared to the wt-ampC sequence of E. 161 
coli strain ATCC 25922. 162 
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Detection of plasmid-mediated ampC beta-lactamase genes.  163 
For the detection of plasmid-mediated ampC beta-lactamase genes a multiplex PCR was 164 
used (17), which detects the six plasmid-mediated ampC families. When necessary, PCR 165 
amplicons were sequenced with the amplification primers following the protocol described 166 
above. Sequences were analyzed for homology using the NCBI Genbank database 167 
(National Center for Biotechnology Information (GenBank), 168 
http://www.ncbi.nlm.nih.gov/). 169 
 170 
Interpretation.  171 
Molecular methods were considered the gold standard for calculation of performance 172 
parameters. Results of the CC-DDS and/or Etest AmpC were considered inconclusive if 173 
visible zones of inhibition were lacking i) with cefotetan or cefoxitin alone, and ii) with 174 
cefotetan-cloxacillin or cefoxitin-cloxacillin. 175 
 176 
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Results 190 
 191 
Analysis of Enterobacteriaceae isolates for AmpC production in clinical isolates 192 
2129 non-duplicate clinical strains of the Enterobacteriaceae family isolated in the 193 
diagnostic microbiological laboratory during a 7-months period were screened for AmpC 194 
production. Species with known chromosomally encoded AmpC beta-lactamases (9) were 195 
not included except E. coli. The majority of the isolates were identified as E. coli (n=1435) 196 
and K. pneumoniae (n=360). (Table 1). 197 
Two hundred and eleven out of the 2129 isolates were categorized as potential AmpC 198 
producers on the basis of i) cefoxitin inhibition zone diameters of ≤18 mm, and/or ii) 199 
cefotetan inhibition zone diameters of ≤16 mm, and/or iii) positive ESBL screening 200 
diameters according to CLSI. To further assess the sensitivity and specificity of the 201 
screening procedure 94 out of 1922 isolates with i) cefoxitin inhibition zones of >18 mm, 202 
ii) cefotetan inhibition zone diameters of >16 mm, and iii) negative ESBL screening 203 
diameters according to CLSI were included into the analysis. In total, 305 isolates (211 204 
potential AmpC producers, 94 negative by the AmpC screening procedure) were 205 
characterized by phenotypic methods, multiplex PCR and, in part, DNA sequence analysis 206 
(gold standard, Figure 2).  207 
Thirty-seven out of 211 of the potential AmpC producers were confirmed as AmpC 208 
producing isolates by phenotypic and molecular methods (Figure 2). One out of 211 isolate 209 
with a CIT type plasmid-encoded AmpC beta-lactamase was detected by molecular 210 
methods exclusively. AmpC production in this isolate was neither detected by the cefoxitin 211 
and cefotetan disk diffusion tests (which showed inhibition zone diameters of 21 mm and 212 
27 mm, respectively), nor by the cefoxitin-cloxacillin double disk synergy test. MICs of 213 
cefoxitin and cefotetan for this isolate were 4 mg/L and 0.75 mg/L, respectively. Both 214 
values are in the susceptible range of the CLSI 2009 guidelines. The majority of plasmid-215 
 9 
encoded AmpCs belonged to the CIT type (22 of 24 isolates), two plasmid-encoded 216 
AmpCs were identified as DHA type.  217 
Prevalence of AmpC production among all tested isolates was 1.8%. Most frequently 218 
AmpC production was observed in E. coli (33 of 38 isolates), of which 19 were plasmid 219 
encoded and 14 due to mutations in the ampC promoter region (Table 1). The majority of 220 
isolates with AmpC production were isolated from urine (52.6%), respiratory tract 221 
(18.4%), rectogenital (7.9%) and  wound (7.9%) specimens. 13.9 % of the specimens 222 
represent swabs without localization indicated originally sent to the laboratory for ESBL 223 
screening. 224 
 225 
Comparison of primary screening markers for AmpC production  226 
Cefoxitin and cefotetan were compared as primary screening markers. For cefoxitin 18 mm 227 
inhibition zone diameter was chosen as cut off and 16mm for cefotetan (CLSI 2009 228 
susceptible breakpoints). Performance parameters were calculated considering molecular 229 
methods as gold standard (multiplex PCR for the detection of plasmid-mediated ampC 230 
beta-lactamase genes and E. coli chromosomal ampC promoter sequence analysis). 231 
Sensitivities of cefoxitin and cefotetan for the detection of AmpC production were 97.4% 232 
and 52.6%, specificities were 78.7% and 99.3%, respectively. Absolute numbers of isolates 233 
and calculated performance parameters are summarized in Table 2. 234 
Figure 1 shows the zone diameter distributions for cefoxitin and cefotetan in all isolates 235 
with a genotypically confirmed ampC. An AmpC screening cut off for cefoxitin of ≤18 236 
mm (CLSI susceptibility breakpoint) missed only one isolate with a genotypically detected 237 
CIT type AmpC that produced a diameter of 21 mm. Plasmid-encoded AmpCs clustered at 238 
a cefoxitin inhibition zone of 6 mm (19 of 24 isolates), which corresponds to the absence 239 
of a visible inhibition zone as the disc diameter itself is 6 mm. For isolates with plasmid-240 
encoded AmpCs the largest cefoxitin inhibition zone observed was 13 mm, in an isolate 241 
that was identified as Salmonella Typhimurium with a CIT type AmpC. In contrast, the 242 
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majority of E. coli isolates with promoter mutations produced inhibition zone diameters of 243 
≥13 mm (10 of 14 isolates). Cefotetan, in general, showed higher variation in zone 244 
diameters than cefoxitin. An AmpC screening cut off of ≤16 mm (CLSI susceptibility 245 
breakpoint) missed all 14 E. coli isolates with AmpC promoter mutations and 5 of 24 246 
isolates with a plasmid-encoded AmpC. All isolates with promoter mutations showed 247 
cefotetan zone diameters of ≥18 mm and the majority of isolates with plasmid-encoded 248 
AmpCs showed cefotetan zone diameters of ≤17 mm (20 of 24 isolates). 249 
 250 
Comparison of confirmation assays for AmpC production 251 
The Etest AmpC and the cefoxitin/cloxacillin CC-DDS method were compared as 252 
phenotypic confirmation tests. In 10 of the 305 isolates the results of the Etest AmpC were 253 
inconclusive since MICs exceeded the scale of the test for cefotetan alone and/or cefotetan 254 
in combination with cloxacillin (Figure 2). Therefore, the calculation of a ratio was not 255 
possible. With the CC-DDS 2 inconclusive results were observed. In these 2 isolates no 256 
inhibition zone was present for cefoxitin alone or in combination with cloxacillin. Isolates 257 
with inconclusive results were not included in the calculation of performance parameters. 258 
Sensitivities for Etest AmpC and CC-DDS were 77.4% and 97.2%, respectively, 259 
specificity was 100% when both methods were combined (Table 2).  260 
 261 
Development of an algorithm for AmpC detection in Enterobacteriaceae 262 
Combining the most sensitive screening method with the most accurate confirmation 263 
assay for AmpC production we developed a comprehensive diagnostic flow-chart (Figure 264 
3), which consists of i) cefoxitin as screening marker for AmpC production and ii) CC-265 
DDS as phenotypic confirmation with iii) molecular methods in case of inconclusive 266 
results. For AmpC detection in the isolates of this study, this diagnostic approach would 267 
have displayed a calculated sensitivity and specificity of 97.4 and 100%, respectively 268 
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(Table 2), with molecular analysis for inconclusive results only necessary for 2 isolates 269 
(1% of all isolates positive in the AmpC screening procedure) 270 
 12 
Discussion 271 
 Detection of AmpC production in pathogens might be important for ensuring effective 272 
antibiotic therapy (20) since the presence of an AmpC beta-lactamase frequently seems to 273 
result in therapeutic failure when using broad-spectrum cephalosporins (14, 24). However, 274 
further studies are required to assess whether AmpC production is an independent risk 275 
factor for clinical outcome. Several single methods have been evaluated for phenotypic 276 
screening and confirmation of AmpC beta lactamases production (9, 25). However, a 277 
comprehensive diagnostic algorithm integrating both screening and confirmation has not 278 
been established. In this study we evaluated individual screening and confirmation 279 
methods for AmpC production. Subsequently, we developed a diagnostic algorithm that i) 280 
combines the most efficient and accurate methods, ii) which is simple, and iii) which can 281 
be implemented in the diagnostic laboratory (Fig.2). 282 
 When cefoxitin and cefotetan (both cephamycins) were compared as the primary 283 
screening marker, cefoxitin was clearly superior to cefotetan regarding sensitivity (see 284 
Table 2). The results for cefoxitin are in agreement with those of other authors (20, 25). 285 
However, specificity in this study was significantly lower, e.g. 78.7% in this study vs. 95% 286 
reported by Tan et al. 2009 (25). . In contrast to MIC determination by automated systems 287 
determination of drug susceptibility by disc diffusion may further enhance sensitivity since 288 
synergy and antagonism phenomena are readily observed, e.g. when placing a cefoxitin 289 
disc near a third generation cephalosporin disc. For example, presence of DHA type 290 
enzymes will lead to flattening of inhibition zones (antagonism phenomena) of third 291 
generation cephalosporins towards inducers like cefoxitin, carbapenems or clavulanic acid. 292 
Otherwise, AAC type enzymes are characteristically inhibited by cefoxitin visible as 293 
enhancement of the inhibition zones (synergy phenomena) of third generation 294 
cephalosporins and cefoxitin. With this strategy detection of ACC type AmpC enzymes is 295 
possible although ACC enzymes appear cefoxitin susceptible (1, 22). In contrast, cefoxitin 296 
screening by MIC alone would miss ACC types. Other authors recommend additional 297 
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screening criteria for ACC enzymes like critical inhibition zone diameters for amoxicillin-298 
clavulanic acid or third generation cephalosporins (26). To date, the ACC types seem to be 299 
the only known enzymes that can be missed by cefoxitin screening. The isolation numbers 300 
of ACC enzymes are still significantly lower than those of CIT (CMY), FOX, and DHA 301 
types (10, 14, 19, 25, 26). No ACC type AmpC was detected in this study.  302 
The AmpC flow-chart (Figure 2) can be combined with a flow-chart for ESBL detection 303 
(manuscript in preparation). If cefoxitin is not routinely tested, an alternative branch may 304 
be chosen that substitutes the cefoxitin screening criteria by CLSI screening criteria for 305 
ESBL (see Fig 3). With a combined ESBL/AmpC screening strategy ACC enzymes will 306 
readily be detected. ACC confers high resistance to third generation cephalosporins, which 307 
serve as primary screening markers for ESBL detection (19, 21). Thus, corresponding 308 
isolates will be assigned to a combined ESBL/AmpC confirmation test via the CLSI 309 
screening criteria for ESBL (5, 6). 310 
The single false-negative result for the cefoxitin screening test in this study (Figure 2) 311 
resulted from the presence of a CIT type ampC detected by multiplex PCR. MICs of this 312 
isolate for cefoxitin and cefotetan were well within the susceptible range, and both 313 
phenotypic confirmation tests were clearly negative (Etest AmpC ratio 1.0, CC-DDS no 314 
difference). Sequence analysis of the CIT ampC gene did not reveal any mutation affecting 315 
structure and/or function of the enzyme. However, mutations in the regulatory regions may 316 
result in very low or non-expression of the structural gene (8). Considering that the CIT 317 
type enzyme in this isolate may be non-functional, the sensitivity of the cefoxitin screening 318 
procedure would be close to 100%. 319 
We compared the performance of the Etest AmpC and the cefoxitin-cloxacillin CC-320 
DDS  as phenotypic confirmation test (25). Boronic acid can be used as alternative to 321 
cloxacillin as AmpC inhibitor, since it was found to be almost as sensitive and specific as 322 
cloxacillin by Tan et al. (25). However, boronic acid may produce false-positive results in 323 
isolates carrying class A carbapenemases, while cloxacillin does not (15, 16). Therefore, 324 
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we chose cloxacillin as AmpC inhibitor in our algorithm. Regarding sensitivity, the CC-325 
DDS was clearly superior to the Etest AmpC (97.2% vs. 77.4%, respectively, see Table 2). 326 
This result may be explained by the use of cefotetan in the Etest AmpC. Cefotetan has a 327 
lower sensitivity than cefoxitin concerning the detection of AmpC production. This is also 328 
apparent when using cefotetan disc diffusion as screening test (see Table 2). Ten 329 
inconclusive results were obtained with the Etest AmpC, due to MICs exceeding the Etest 330 
scale of cefotetan with and without cloxacillin (Table 2). In routine use this may hamper 331 
sensitivity and practicability of the method. In contrast, with CC-DDS only 2 inconclusive 332 
results were obtained. For both isolates with an inconclusive result no inhibition zone for 333 
cefoxitin was observed both with and without cloxacillin. Eventually, AmpC enzymes of 334 
the CIT type were found in both strains. The results for the CC-DDS are in agreement with 335 
other studies that reported a high sensitivity and specificity for this test (25).  336 
Combining the high sensitivity of cefoxitin screening with the high specificity of the 337 
cefoxitin/cloxacillin CC-DDS confirmation test we propose a flow-chart for phenotypic 338 
detection and characterization of AmpC beta-lactamases (Fig 3). In case of (rarely 339 
occurring) inconclusive results, molecular methods are used for resolution. The proposed 340 
flow-chart would have a calculated sensitivity and specificity of 97.4% and 100%, 341 
respectively, with respect to the isolates of this study. Phenotypic AmpC screening and 342 
confirmation tests are inexpensive, but nevertheless highly sensitive and specific. 343 
Therefore it can be performed in all types of clinical laboratories while implementation of 344 
molecular methods is often complex, needs specially trained personnel, and is associated 345 
with higher costs.  346 
.In conclusion, the proposed flow-chart for detection of AmpC is simple to use, and 347 
easy to implement in a diagnostic laboratory. If molecular methods are not available, the 348 
few inconclusive isolates can be submitted to a reference laboratory for further 349 
investigations. In parallel we have developed a flow-chart for ESBL detection (manuscript 350 
in preparation), which in combination with the AmpC detection flow-chart covers a broad 351 
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spectrum of beta-lactamases, facilitating therapeutical decisions and epidemiological 352 
surveillance. 353 
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 Table 1: Species distribution and numbers of AmpC producing Enterobacteriaceae isolates 478 
 479 
 480 
 481 
 482 
 483 
 484 
 485 
 486 
 487 
 488 
 489 
 490 
  Numbers are given for all Enterobacteriaceae species that were tested for antibiotic susceptibility;  491 
a) 19 E. coli strains harboured a plasmidic ampC, 14 E. coli strains contained mutations in the chromosomal ampC promoter which resulted in 492 
overexpression. E. coli strains with both plasmidic ampC and chromosomal ampC promoter mutations present were not detected.  493 
 494 
 495 
 N  (% of isolates) 
ampC positive  
isolates 
(% of species 
isolates) 
 
    
Escherichia coli 1435 (67.4) 33 (2.3)a 
 
    
Klebsiella pneumoniae 360 (16.9) 2 (0.6) 
 
    
Klebsiella oxytoca 99 (4.7) 0  
 
    
Salmonella enterica 4 (0.2) 2 (50.0) 
 
    
Proteus vulgaris 26 (1.2) 0  
 
    
Proteus mirabilis 131 (6.2) 1 (0.8) 
 
    
Citrobacter koseri 74 (5.2) 0  
 
    
Total 2129 (100) 38  
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Table 2: Performance of screening tests, confirmation tests and the proposed AmpC detection algorithm. 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
TP, true positive; TN, true negative; FP, false positive; FN, false negative. a) Results were rated inconclusive if MICs exceeded the scale 506 
of the Etest for cefotetan alone and/or cefotetan in combination with cloxacillin (Etest AmpC) or when no inhibition zone could be 507 
detected for both cefoxitin alone or in combination with cloxacillin (CC-DDS). Inconclusive results were excluded from the calculation 508 
of performance parameters. 509 
 510 
 511 
Method Isolates 
(N) 
TP FP TN FN Inconclusive 
resultsa 
Sensitivity % Specificity % 
Screening methods         
 
        
Cefoxitin Screening 305 37 57 210 1 0 97.4 78.7 
 
        
Cefotetan Screening 305 20 2 265 18 0 52.6 99.3 
 
        
Confirmation tests         
 
        
Etest AmpC  305 24 0 264 7 10 77.4 100.0 
 
        
Cefoxitin +/- Cloxacillin 305 35 0 267 1 2 97.2 100.0 
 
        
AmpC Algorithm 305 37 0 267 1 0 97.4 100.0 
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Figure 1: Inhibition zone diameter distributions in AmpC beta-lactamase producing isolates  512 
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Inhibition zone diameters of cefoxitin (A) and cefotetan (B). Number of Enterobacteriaceae isolates with 515 
plasmidic ampC (grey bars) and chromosomal ampC promoter mutations (black bars, E. coli only); CLSI 516 
2009 susceptibility breakpoints (black arrows). 517 
 518 
 519 
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B 
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Figure 2: Study layout and  numbers of isolates 
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 #) AmpC missed by the algorithm. 
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Figure 3: Flow-chart for detection of AmpC beta-lactamase production in Enterobacteriaceae 
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a
AmpC screening:
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a) includes Enterobacteriaceae spp with no known chromosomal ampC production plus E. coli. 
b) difference of zone diameters “inconclusive” means no visible inhibition zones around both cefoxitin discs with 
and without cloxacillin. pampC, plasmidic AmpC beta-lactamase.  
c) mutations in the ampC promoter region of E. coli that result in overexpression of ampC . 
